Oncology · Hormonal TherapyRegulatory Approvalregulatorymid-term

FDA Grants Abiraterone Acetate ANDA208371 Approval Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/22/2026, 6:32:31 PM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval status for Abiraterone Acetate under application ANDA208371 indicates a significant regulatory milestone that could alter competitive dynamics in the oncology market. Portfolio teams must evaluate how this impacts pricing and market strategies for existing therapies. Regulatory context from FDA (FDA AP — ABIRATERONE ACETATE (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on pricing and market entry strategies for competing products. The strongest clinical anchor is A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Hormonal Therapy, 7 regulatory and 4 competitive items passed relevance filtering for Abiraterone Acetate.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA approves capivasertib with abiraterone for PTEN-deficient prostate cancer. This approval status may impact the market dynamics for Abiraterone Acetate, especially against existing therapies in the oncology space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ABIRATERONE ACETATE (SUPPL) (FDA). Entity match (abiraterone acetate); Regulatory pathway relevance (nda). The 'Approved Pending' status suggests that while the application is progressing, final approval and market entry timelines remain uncertain, which could affect compliance and operational planning.

Key Risks

Elevated medium regulatory exposure for Abiraterone Acetate could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval status may influence market share and pricing strategies for competing oncology products, potentially affecting revenue streams.
Upside for Abiraterone Acetate may improve if Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. (PubMed) delivers favorable follow-through.
Upside for Abiraterone Acetate may improve if Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the implications of this approval on pricing and market entry strategies for competing products.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval decision and any subsequent market entry timelines for RISING's product.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ABIRATERONE ACETATE (SUPPL)
FDAhigh relevance
Entity match (abiraterone acetate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CETRORELIX ACETATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CALCIUM ACETATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUPROLIDE ACETATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUPROLIDE ACETATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUPROLIDE ACETATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUPROLIDE ACETATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effects of Physiotherapy in Migraine
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of Acceptance and Commitment Therapy and Cognitive Behavior Therapy: Managing Psychological Distress and Its Multifaceted Impact on Stigmatization, Psychological Wellbeing, Social Support a
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA approves capivasertib with abiraterone for PTEN-deficient prostate cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
FDA Grants Approval for Gallium Ga-68 Gozetotide (ANDA216410)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Thalidomide ANDA213267 by NATCO
Humanexa Signalsmedium relevance
Moderate corpus alignment

Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Restoring ovulation in functional hypothalamic amenorrhea: impact of polycystic ovarian morphology on hormonal response to pulsatile GnRH.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Opsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence treatment.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
NK cell-based immunotherapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Abiraterone Acetate

Commercial impact

medium

The approval status may influence market share and pricing strategies for competing oncology products, potentially affecting revenue streams.

Regulatory impact

medium

The 'Approved Pending' status suggests that while the application is progressing, final approval and market entry timelines remain uncertain, which could affect compliance and operational planning.

What to watch

Monitor the final approval decision and any subsequent market entry timelines for RISING's product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.